ECT
ECT (European Computer Telecoms AG), Europe’s leading communications software company for the realization of value-added services, announces that the company again achieved record growth in 2019. The company experienced an annual order intake of over 23 million EUR. Although the company’s audited, consolidated annual report has yet be completed, it is already clear that in 2019 ECT exceeded the 20% top-line growth achieved in the previous year, while the bottom line grew by over 30%. In addition, due to the high order backlog at the close of 2019 and maintenance contracts for 2020, ECT already has more than 12 million EUR on its books for this year and anticipates continued record growth.
This landmark development is in line with the Board’s long-term goal of maintaining at least 20% year-to-year revenue growth. As Marshall E. Kavesh, the CEO and cofounder of ECT, explains, “after more than 20 years as a profitable, but midsized market player, we last year took on the ambitious goal of growing ECT from a 20 million Euro to a 100 million Euro company by no later than 2025. With the excellent results of the last two years we have made important steps in this direction. Our continued growth, profitability, customer relationships and innovations are the foundation for the long-term prosperity and independence of our company. This is a commitment we make to all the colleagues in our fantastic ECT team and especially to our much appreciated customers.”
Key highlights for 2019 include:
Expanded Depth and Breadth of Customer Relationships
- The vast majority of the orders were received from first-tier carriers which have been ECT customers for 10 years and longer, attesting to the deep satisfaction of the company’s customer base.
- In addition, the company, whose roots are in Europe, continued to expand its footprint in the Americas with new customer acquisitions and conducted direct sales worldwide.
- With one of Finland’s leading telecommunications operators, DNA, the company closed a three-year contract worth many millions of euros for the provision of, amongst other things, licenses for ECT’s application for Virtual PBX / Unified Communications, a license for the Service Creation Environment of the company’s Telephony Application Server (TAS) as well as the utilization of a Dedicated Agile Programming Squad .
- In indirect sales via its partner Nokia Software, the company took part in tenders worldwide, e.g. closing yet another major multimillion deal.
Major Investments in Cutting-Edge Telecoms Technology
- The company founded a new R&D unit for NFVi architecture, implemented integration with Nokia’s CloudBand Application Manager (CBAM) and plans to continue certification with other major VNF Managers in 2020. Few competitors are capable of offering this important, cost-reducing technology.
- All new solutions are implemented based on ECT’s VNFs with the option of full integration with a third-party VNF Manager, providing Automated Lifecycle Management.
- ECT implemented agile methodology throughout the company starting in January 2019 and also launched a program allowing CSPs to take under contract an ECT Dedicated Agile Programming Squad, enabling them to respond in extremely short cycles to the customizations and enhancements demanded by their major corporate and municipal customers.
- Within the framework of ECT’s Joint Agile Product Development, the company’s Innovation Department successfully launched its cutting-edge application for unified communications and collaboration, ECT Workspace, with selected CSPs.
Rapid Organization Growth
- Although many other telecoms vendors are in retrenchment, ECT is accelerating the growth of its team: In 2019, the number of employees increased by ca. 25% compared to 2018 and is expected to grow by at least another 25% by the end of this year, the majority of the new positions being in R&D.
About ECT (European Computer Telecoms AG):
For more information about ECT, please visit our website: www.ect-telecoms.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 13:00:00 CET | Press release
Visa Consulting & Analytics combines advanced payments strategy and expert crypto knowledge to help clients innovate and grow with stablecoins technology Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press release
Safe Software named for the 6th consecutive time in Gartner® Magic Quadrant™ Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo sikrer OCC-godkendelse til konvertering til føderalt chartret National Trust Bank13.12.2025 02:12:00 CET | Pressemeddelelse
Sætter ny standard for institutionel digital aktivinfrastruktur med samlet føderal tilsyn BitGo Holdings, Inc. (“BitGo”), virksomheden inden for digital aktivinfrastruktur, annoncerede i dag, at Office of the Comptroller of the Currency (“OCC”) godkendte virksomhedens ansøgning om at konvertere BitGo Trust Company, Inc., et trustselskab registreret i South Dakota, til en nationalbank ved navn BitGo Bank & Trust, National Association (N.A.). Med dagens OCC-godkendelse af konverteringen fungerer BitGos datterselskab af Trust Company nu som BitGo Bank & Trust, National Association (N.A.). BitGo Bank & Trust, N.A. vil operere under et enkelt, ensartet føderalt tilsynssystem, der gør det muligt at levere den klarhed, styring og reguleringssikkerhed, som institutioner forventer af et føderalt reguleret fiduciært selskab. Denne godkendelse styrker BitGos position som et institutionelt fundament for det moderne finansielle system, der kombinerer tilsyn på bankniveau med den sikkerhed, complian
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom